Safety concerns prompted Titan Pharmaceuticals Inc. to stop a year-old Phase IIb study of its cancer drug Pivanex. The South San Francisco-based company said an interim analysis by an independent data monitoring committee identified safety issues in the combination treatment of Pivanex with docetaxel for non-small-cell lung cancer patients. Titan …
Комментариев нет:
Отправить комментарий